Last reviewed · How we verify
Lactobacillus casei variety rhamnosus granules
Lactobacillus casei variety rhamnosus granules is a Probiotic / Live biotherapeutic product Small molecule drug developed by Seoul National University Hospital. It is currently FDA-approved for Gastrointestinal health maintenance, Diarrhea prevention and treatment, Immune system support. Also known as: RAMNOS GRANULS.
Lactobacillus casei variety rhamnosus is a probiotic bacterium that colonizes the gut and modulates the intestinal microbiota and immune system.
Lactobacillus casei variety rhamnosus is a probiotic bacterium that colonizes the gut and modulates the intestinal microbiota and immune system. Used for Gastrointestinal health maintenance, Diarrhea prevention and treatment, Immune system support.
At a glance
| Generic name | Lactobacillus casei variety rhamnosus granules |
|---|---|
| Also known as | RAMNOS GRANULS |
| Sponsor | Seoul National University Hospital |
| Drug class | Probiotic / Live biotherapeutic product |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Immunology |
| Phase | FDA-approved |
Mechanism of action
This live biotherapeutic product works by restoring beneficial bacterial populations in the gastrointestinal tract, which helps maintain intestinal barrier function, promotes the growth of other beneficial microorganisms, and stimulates local and systemic immune responses. The strain produces metabolites and interacts with intestinal epithelial cells and immune cells to support digestive health and immune homeostasis.
Approved indications
- Gastrointestinal health maintenance
- Diarrhea prevention and treatment
- Immune system support
Common side effects
- Gastrointestinal disturbance
- Bloating
- Flatulence
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lactobacillus casei variety rhamnosus granules CI brief — competitive landscape report
- Lactobacillus casei variety rhamnosus granules updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI
Frequently asked questions about Lactobacillus casei variety rhamnosus granules
What is Lactobacillus casei variety rhamnosus granules?
How does Lactobacillus casei variety rhamnosus granules work?
What is Lactobacillus casei variety rhamnosus granules used for?
Who makes Lactobacillus casei variety rhamnosus granules?
Is Lactobacillus casei variety rhamnosus granules also known as anything else?
What drug class is Lactobacillus casei variety rhamnosus granules in?
What development phase is Lactobacillus casei variety rhamnosus granules in?
What are the side effects of Lactobacillus casei variety rhamnosus granules?
Related
- Drug class: All Probiotic / Live biotherapeutic product drugs
- Manufacturer: Seoul National University Hospital — full pipeline
- Therapeutic area: All drugs in Gastroenterology / Immunology
- Indication: Drugs for Gastrointestinal health maintenance
- Indication: Drugs for Diarrhea prevention and treatment
- Indication: Drugs for Immune system support
- Also known as: RAMNOS GRANULS
- Compare: Lactobacillus casei variety rhamnosus granules vs similar drugs
- Pricing: Lactobacillus casei variety rhamnosus granules cost, discount & access